Sonoma Pharmaceuticals, Inc. (SNOA) Institutional Ownership

Ownership Summary

The institutional landscape for Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) includes 15 filers as of the latest reporting cycle ending December 2025.

• These investors collectively held 6.4% of the company's total shares outstanding in December 2025, up from 3.6% in September 2025.
• Institutional share ownership changed by 88.01% QoQ, while the number of institutional owners saw an increase of 50.00% YoY.
• During the quarter, 5 institutions bought more Sonoma Pharmaceuticals shares, 5 sold shares, and 5 of the 15 total investors held their position steady.
• The total number of shares held by institutions in Sonoma Pharmaceuticals increased to 108.91K as of December 2025, a net change of up by 50.98K shares quarter on quarter, and up 88.75K shares year over year.
• The top institutional stake in Sonoma Pharmaceuticals as of December 31, 2025 belongs to DRW Securities, LLC, which owns 60.98K shares, or 3.57% of the company.
• Among the most significant buyers of Sonoma Pharmaceuticals during December 2025 were DRW Securities, LLC (43.91K), McKinley Carter Wealth Services, Inc. (11.19K), OSAIC HOLDINGS, INC. (500), Global Retirement Partners, LLC (334), BANK OF AMERICA CORP /DE/ (1).
• Leading sellers of Sonoma Pharmaceuticals stock in December 2025 included VANGUARD GROUP INC (1.99K), GEODE CAPITAL MANAGEMENT, LLC (1.71K), Tower Research Capital LLC (TRC) (1.15K), UBS Group AG (102), JPMORGAN CHASE & CO (2).
• The top 10 institutional holders of Sonoma Pharmaceuticals for the quarter ending December 2025 included DRW Securities, LLC (60.98K), VANGUARD GROUP INC (18.89K), GEODE CAPITAL MANAGEMENT, LLC (15.91K), McKinley Carter Wealth Services, Inc. (11.19K), Global Retirement Partners, LLC (772), OSAIC HOLDINGS, INC. (500), Tower Research Capital LLC (TRC) (385), JPMORGAN CHASE & CO (121), BlackRock, Inc. (113), US BANCORP \DE\ (25).